Literature DB >> 16645017

Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects.

Harald Jörn Schneider1, Bernhard Saller, Jens Klotsche, Winfried März, Wolfgang Erwa, Hans-Ullrich Wittchen, Günter Karl Stalla.   

Abstract

OBJECTIVE: Insulin-like growth factor-I (IGF-I) has been suggested to be a prognostic marker for the development of cancer and, more recently, cardiovascular disease. These diseases are closely linked to obesity, but reports of the association of IGF-I with measures of obesity are divergent. In this study, we assessed the association of age-dependent IGF-I standard deviation scores with body mass index (BMI) and intra-abdominal fat accumulation in a large population.
DESIGN: A cross-sectional, epidemiological study.
METHODS: IGF-I levels were measured with an automated chemiluminescence assay system in 6282 patients from the DETECT study. Weight, height, and waist and hip circumference were measured according to the written instructions. Standard deviation scores (SDS), correcting IGF-I levels for age, were calculated and were used for further analyses.
RESULTS: An inverse U-shaped association of IGF-I SDS with BMI, waist circumference, and the ratio of waist circumference to height was found. BMI was positively associated with IGF-I SDS in normal weight subjects, and negatively associated in obese subjects. The highest mean IGF-I SDS were seen at a BMI of 22.5-25 kg/m2 in men (+0.08), and at a BMI of 27.5-30 kg/m2 in women (+0.21). Multiple linear regression models, controlling for different diseases, medications and risk conditions, revealed a significant negative association of BMI with IGF-I SDS. BMI contributed most to the additional explained variance to the other health conditions.
CONCLUSIONS: IGF-I standard deviation scores are decreased in obesity and underweight subjects. These interactions should be taken into account when analyzing the association of IGF-I with diseases and risk conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16645017     DOI: 10.1530/eje.1.02131

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  20 in total

Review 1.  Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

Authors:  David R Clemmons
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

2.  Chronic activity-based therapy does not improve body composition, insulin-like growth factor-I, adiponectin, or myostatin in persons with spinal cord injury.

Authors:  Todd A Astorino; Eric T Harness; Kara A Witzke
Journal:  J Spinal Cord Med       Date:  2014-08-17       Impact factor: 1.985

Review 3.  IGF-I/IGFBP system: metabolism outline and physical exercise.

Authors:  R Gatti; E F De Palo; G Antonelli; P Spinella
Journal:  J Endocrinol Invest       Date:  2012-06-18       Impact factor: 4.256

4.  Epidemiologic survey: reference ranges of serum insulin-like growth factor 1 levels in Caucasian adult population with immunoradiometric assay.

Authors:  Fahri Bayram; Vedia Tonyukuk Gedik; Özgür Demir; Ahmet Kaya; Kürşat Gündoğan; Rıfat Emral; Ahmet Öztürk; Ali Rıza Uysal; Demet Çorapçıoğlu
Journal:  Endocrine       Date:  2011-05-03       Impact factor: 3.633

Review 5.  How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children?

Authors:  Anna Pawlikowska-Haddal; Pinchas Cohen; David M Cook
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

6.  Does IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma?

Authors:  C T Bahadir; G C Ecemis; H Atmaca
Journal:  J Endocrinol Invest       Date:  2018-03-14       Impact factor: 4.256

7.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.

Authors:  Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey
Journal:  Cell Metab       Date:  2009-04       Impact factor: 27.287

8.  Genetic susceptibility to distinct bladder cancer subphenotypes.

Authors:  Lin T Guey; Montserrat García-Closas; Cristiane Murta-Nascimento; Josep Lloreta; Laia Palencia; Manolis Kogevinas; Nathaniel Rothman; Gemma Vellalta; M Luz Calle; Gaëlle Marenne; Adonina Tardón; Alfredo Carrato; Reina García-Closas; Consol Serra; Debra T Silverman; Stephen Chanock; Francisco X Real; Núria Malats
Journal:  Eur Urol       Date:  2009-08-12       Impact factor: 20.096

Review 9.  The current status of IGF-I assays--a 2009 update.

Authors:  Jan Frystyk; Pamela Freda; David R Clemmons
Journal:  Growth Horm IGF Res       Date:  2009-10-08       Impact factor: 2.372

10.  IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea.

Authors:  Daniel A Heinrich; Claudia Reinholz; Maximilian Bauer; Amanda Tufman; Richard Frohner; Jochen Schopohl; Martin Bidlingmaier; Robert P Kosilek; Martin Reincke; Harald J Schneider
Journal:  Endocrine       Date:  2018-01-31       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.